Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, has entered into a collaboration and option agreement with Japanese company, Ono Pharmaceutical Co., Ltd, for novel treatments targeting fibro-inflammatory diseases.
These diseases are characterised by myofibroblast activation, scarring, inflammation and tissue remodelling, which can lead to organ failure and complications.
Under the terms of the agreement, Ono will partner with Mediar, leveraging the company’s fibrosis-focused discovery platform, myofibroblast expertise and understanding of key fibrosis pathways.
Ono will have an exclusive option to license worldwide rights to develop and commercialise the programmes, making an upfront payment to Mediar and supporting R&D costs.
